Mesenchymal stromal cell therapy attenuated lung and @entity8 but not brain damage in experimental XXXX .

@entity32 @entity8 @entity39 @entity19 @entity4 @entity5 @entity3806 @entity5895 @entity6197 @entity4801 @entity311 @entity204 @entity2637
INTRODUCTION: @entity311 is the most relevant @entity4801 worldwide, and still accounts for 1 million deaths each year. Since current antimalarial drugs are unable to prevent @entity204 in severe cases, new therapeutic strategies have been developed. Mesenchymal stromal cells (MSC) confer host resistance against @entity311 ; however, thus far, no study has evaluated the therapeutic effects of MSC therapy on brain and distal organ damage in experimental @entity6197 . METHODS: Forty C57BL/6 @entity19 were injected intraperitoneally with 5   *   10(6) @entity2637 -infected erythrocytes or saline. After 24  h, @entity19 received saline or bone marrow (BM)-derived MSC (1x10(5)) intravenously and were housed individually in metabolic cages. After 4  days, lung and kidney morphofunction; cerebrum, spleen, and liver histology; and markers associated with @entity32 , fibrogenesis, and epithelial and endothelial cell damage in lung tissue were analyzed. RESULTS: In @entity2637 -infected @entity19 , BM-MSCs: 1) reduced @entity5895 and mortality; 2) increased phagocytic neutrophil content in brain, even though BM-MSCs did not affect the inflammatory process; 3) decreased @entity311 pigment detection in spleen, liver, and kidney; 4) reduced hepatocyte derangement, with an increased number of Kupffer cells; 5) @entity8 , without effecting significant changes in serum creatinine levels or urinary flow; and 6) reduced neutrophil infiltration, @entity4 , number of myofibroblasts within interstitial tissue, and collagen deposition in lungs, resulting in decreased lung static elastance. These morphological and functional changes were not associated with changes in levels of @entity5 @entity39 factor-a, keratinocyte-derived chemokine (KC, a @entity19 analog of @entity3806 ), or interferon-y, which remained increased and similar to those of @entity2637 animals treated with saline. BM-MSCs increased hepatocyte growth factor but decreased VEGF in the @entity2637 group. CONCLUSIONS: BM-MSC treatment increased survival and reduced @entity5895 and @entity311 pigment accumulation in spleen, liver, kidney, and lung, but not in brain. The two main organs associated with worse prognosis in @entity311 , lung and kidney, sustained less histological damage after BM-MSC therapy, with a more pronounced improvement in lung function.
